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1. Introduction
One of the oldest diseases of mankind is diabetes mellitus. It was only during the later part 
of the nineteenth and first half of the twentieth centuries that newer advances relating to 
the pathology, predisposing factors, management, course and complications of diabetes 
mellitus were discovered. Yet many more demanding solutions relating to the disease are 
still required. It has been seen that urbanisation and ageing of the population is definitely 
related to diabetes mellitus. But it is also true that diabetes mellitus affects all ages and 
all races. It has been estimated that around 400 million people will be affected by diabetes 
mellitus by 2030 AD. There are three principal forms of diabetes mellitus: type 1, type 2 
and gestational diabetes mellitus (GDM). It has been seen that Finland has one of the high-
est incidence rates of type 1 diabetes mellitus. Type 1 diabetes is most likely a polygenic 
disease and has a number of potential risk factors. Type 2 diabetes is associated with the 
interaction of environmental factors and genetic factors. Impaired glucose tolerance (IGT), 
which has a great potential to be converted to diabetes mellitus, also carries cardiovas-
cular and other risks. It has been seen that the important risk factors for the occurrence 
of diabetes are (i) changes in lifestyle due to urbanisation, (ii) hereditary, (iii) resistance 
to insulin, (iv) accumulation of fat around the waist rather than generalised obesity, (v) 
increasing age and (vi) ethnicity. It has been seen that long-standing diabetes mellitus is 
associated with an increased prevalence of macrovascular and microvascular diseases. 
Other chronic complications such as neuropathy and retinopathy are very common in 
diabetes mellitus.
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2. Historical perspective of insulin
Although diabetes mellitus was always recognised as a distinct entity for more than 3000 years, 
its exact cause was not known until the twentieth century.
Till the early 1920s, many investigators were of the strong suspicion that diabetes was caused 
by a malfunction in the digestive system related to the pancreas gland. During that time the 
fatal disease was treated by a diet which was low in sugar and carbohydrates and high in 
protein and fat.
In those days, the patient usually died shortly after diagnosis, but the above diet allowed 
them to live for some years.
However, Best and Banting [1], Figure 1, two Canadians, provided a great relief to the world 
when they were able to isolate insulin from canines. They first produced diabetogenic symp-
toms in dogs and then with the help of insulin injections returned the dogs to normalcy. On 
the morning of November 14, 1921, they announced their discovery to the world. Then on 
January 23, 1922, they first injected Canadian 14-year-old Leonard Thompson with insulin 
and continued the treatment for diabetes mellitus.
Banting [2], Figure 2, by virtue of his tedious research, was able to create a pancreatic extract, 
which enabled him to gather thousands of islet cells. He then prepared extracts of insulin 
from these islets.
Initially, the insulin was tested on dogs, and it was able to regulate their blood glucose levels. 
Then in 1922 they tested it on Leonard Thompson, who became the first human being to be 
Figure 1. Charles Herbert Best, CC, CH, CBE, FRS, FRSC, FRCP (February 27, 1899–March 31, 1978) and Sir Frederick 
Grant Banting, KBE, MC, FRS, FRSC, (November 14, 1891–February 21, 1941) (Source: [1]).
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given insulin. The first dose was a failure as it was not purified enough, but the second dose 
which was purified by James B. Collip proved to be successful.
Development of insulin was done further by Banting along with laboratory director John 
MacLeod, and both of them were awarded the Nobel Prize in Physiology of Medicine in 1923.
The first person who promoted the benefits of a low-carbohydrate diet was Banting [3], Figure 3, 
originally referred to as the ‘Banting diet’. After almost a period of 150 years post his publication 
of the renowned booklet ‘Letter on Corpulence’, addressed to the public (in the year 1863), the 
Banting diet has been backed up by several clinical trials as being safe and effective for weight 
loss, and it is now finally being acknowledged as a beneficial diet for people with diabetes.
It should be noted that Banting was not a scientist, but a highly skilful carpenter. While he 
was young, Banting became overweight, and he was told by a doctor to exercise more. But 
it did not help him. He tried a variety of weight loss options but failed in almost all of them.
Then he met Harvey who told him to give up butter, bread, milk, beer, sugar and potatoes—
i.e. foods which contained sugar and starch. After 5 months, Banting returned to normal 
weight and he was more agile.
Best [4], Figure 4, also helped Frederick Banting in discovering insulin in 1922 after he became 
Banting’s assistant in the summer of 1921. After being awarded the Nobel Prize in 1923 with 
Figure 2. Sir Frederick Grant Banting, KBE, MC, FRS, FRSC (November 14, 1891–February 21, 1941) (Source: [2]).
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Figure 3. William Banting (c. December 1796–March 16, 1878) (Source: [3]).
Figure 4. Charles Herbert Best, CC, CH, CBE, FRS, FRSC, FRCP (February 27, 1899–March 31, 1978) (Source: [4]).
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J.J.R. MacLeod, Banting shared the prize money with Best and the rest of his team that were 
responsible for insulin being developed. Best was instrumental in doing the chemical tests to 
measure blood glucose levels while working with the team.
Thompson [5], Figure 5, was the first patient having diabetes to receive insulin injections on 
January 11, 1922. Almost facing death, Leonard survived for another 13 years. Leonard, who 
was diagnosed some years previously, was admitted in Toronto General Hospital.
He was severely diabetic and was coming in and out of a diabetic coma and was weighing 
only 65 pounds. It was Leonard’s father who gave the consent that his son should be the first 
person to test insulin, which was never previously been tried on another human being.
Initially the impure form of insulin was unable to make any impact in Leonard’s condition; 
however, a purer version of insulin made him survive and his parameters came back to 
normal.
One of the most unique approaches to diabetes treatment was provided by Proctor [6], 
Figure 6, in the early 1900s, as he concentrated on patients taking their own responsibility.
Joslin made his mother survive through diabetes for 10 years through a rigorous combina-
tion of exercise, meal planning and food management. He was the founder of Joslin Diabetes 
Center.
The ‘starvation diet’ was first proposed by Allen [7], Figure 7, who proposed it before the 
discovery of insulin to increase the life span of diabetes patients.
Figure 5. Leonard Thompson (Source: [5]).
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Figure 7. Frederick Madison Allen (1879–1964) (Source: [7]).
Figure 6. Elliott Proctor Joslin, MD (June 6, 1869–January 28, 1962) (Source: [6]).
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It was Allen, a physician, who first proposed that restriction in calorie intake and engaging one-
self in regular exercise resulted in the prolongation of the life of insulin-producing beta cells.
3. Early research
Allen, who was born in Iowa, studied medicine at the University of California. He attended 
Harvard Medical School between 1909 and 1912, and thanks to his father’s financing, he also 
published Studies on Diabetes and Glycosuria in 1913.
Insulin receptors were thoroughly studied mostly by Kahn [8], Figure 8. He spent most of his 
career investigating the role of insulin sensitivity in obesity and diabetes.
Kahn currently works as the Chief Academic Officer and Head of Joslin’s Section on Integrative 
Physiology and Metabolism at the Joslin Diabetes Center.
He thoroughly investigated how cells are affected by insulin and the reason behind why only 
a particular group of cells develops insulin resistance, which is one of the main causes of type 
2 diabetes.
Figure 8. Carl Ronald Kahn (born January 14, 1944) (Source: [8]).
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Kahn through his excellence in diabetes study became Research Director of Joslin and 
Associate Professor of Medicine at Harvard Medical School in 1981 and 1984. He was the 
first to discover the importance of the role of insulin actions in the brain and the causation of 
metabolic diseases by fat cells.
Bouchardat [9], Figure 9, is considered as the founder of diabetology, who helped in the treat-
ment of diabetic patients before the creation of insulin in 1922. He was the first clinician who 
educated patients of diabetology to become aware of the disease. He also stressed the impor-
tance of exercise and urine glucose self-monitoring in the treatment of diabetes. He was the 
pioneer of advising against taking of sugars and starchy food to reduce glycosuria. He was 
also the first to hypothesise the location of diabetes in the pancreas.
Bouchardat wrote and published a number of books on diabetes, amongst them is his most 
well-known work ‘De la Glycosurie ou diabète sucré, son traitement hygénigue’.
It was Collip [10], Figure 10, a biochemist, who played an important role in the production of 
the first insulin dose that was found to be appropriate for injection into humans.
The credit for the discovery of insulin goes to Banting and Best, but their extract was raw and 
failed to produce beneficial effects after being administered to Leonard Thompson, the first 
human to receive it.
Figure 9. Apollinaire Bouchardat (July 23, 1809 – April 7, 1886), a French pharmacist and hygienist born in L’Isle-sur-Serein 
(Source: [9]).
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Collip took up the job of purifying the extract within a period of 2 weeks, and it was again 
administered to Thompson. During the second time, the insulin extract stabilised Thompson’s 
blood glucose levels, which saved his life.
Pancreatic diabetes was discovered by Minkowski [11], Figure 11. Minkowski studied at the 
University of Konigsberg before becoming a professor in Strasburg in 1888. Minkowski was a 
pioneer in the procedure of pancreatectomy in dogs.
White [12] was the pioneer of research into diabetic woman during pregnancy; it led to the 
White classification which is being used to assess diabetes during pregnancy (Figure 12).
This classification is still used today to differentiate between existing diabetes before preg-
nancy and gestational diabetes. The White classification established her in the diabetes history.
The secretion of insulin is an energy requiring process which involves the microtubule-micro-
filament system in beta cells of the islets of Langerhans. Varied numbers of mediators have 
been implicated in the release of insulin.
The level of glucose in the interstitial fluid regulates the activity of the beta cells. A sharp 
increase of 8–10 in the secretion of insulin usually occurs in response to an increase in plasma 
glucose from 70 to 150 mg/dl. During the same phase, a simultaneous decrease in the secre-
tion of glucagon from A cell occurs. There is a greater B-cell response observed following oral 
as opposed to intravenous glucose administration. This is known as ‘incretin’ effect.
Of major importance, defects in the below-stated portions of the hormone’s properties and 
journey in the body have been correlated and are most often related to hypertension, insulin 
resistance and type 2 diabetes [13–19].
Figure 10. James Bertram Collip, CBE, FRS, FRSC, FRCP, FRCPC (November 20, 1892–June 19, 1965) (Source: [10]).
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Figure 12. Priscilla White (March 17, 1900–December 16, 1989) (Source: [12]).
Figure 11. Oskar Minkowski (January 13, 1858–July 18, 1931) (Source: [11]).
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The journey of insulin can be divided into five stages, which can be related to insulin resis-
tance and type 2 diabetes:
• Diabetic cell having defective insulin exocytosis [20–25].
• Defect in the vasoactive properties of insulin during insulin resistance, which includes cap-
illary recruitment [22, 26–29].
• The GLUT4 translocation to the muscle membrane is diminished in humans [14, 22, 30–36].
• Decreased hepatic clearance of insulin [37] and CEACAM1 expression [38] in obesity.
• There is compromised glomerular function in obese people [22, 39–41].
Most of it is routed to the lysosome for degradation. But most of the degradation of the circu-
lating hormone remaining after second pass through the liver continues in the kidney.
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